141 related articles for article (PubMed ID: 36729612)
21. Proof of Concept of the Radiosensitizing Effect of Gadolinium Oxide Nanoparticles in Cell Spheroids and a Tumor-Implanted Murine Model of Chondrosarcoma.
Aloy MT; Sidi Boumedine J; Deville A; Kryza D; Gauthier A; Brichart-Vernos D; Ollier G; La Padula V; Lux F; Tillement O; Rodriguez-Lafrasse C; Janier M
Int J Nanomedicine; 2022; 17():6655-6673. PubMed ID: 36582458
[TBL] [Abstract][Full Text] [Related]
22. PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation.
Jonuscheit S; Jost T; Gajdošová F; Wrobel M; Hecht M; Fietkau R; Distel L
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34073147
[TBL] [Abstract][Full Text] [Related]
23. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
[TBL] [Abstract][Full Text] [Related]
24. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.
Monderer D; Luseau A; Bellec A; David E; Ponsolle S; Saiagh S; Bercegeay S; Piloquet P; Denis MG; Lodé L; Rédini F; Biger M; Heymann D; Heymann MF; Le Bot R; Gouin F; Blanchard F
Lab Invest; 2013 Oct; 93(10):1100-14. PubMed ID: 23958880
[TBL] [Abstract][Full Text] [Related]
25. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
26. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of PARP inhibition in enhancing the radiosensitivity of 3D spheroids of head and neck squamous cell carcinoma.
Zhou C; Fabbrizi MR; Hughes JR; Grundy GJ; Parsons JL
Front Oncol; 2022; 12():940377. PubMed ID: 36052247
[TBL] [Abstract][Full Text] [Related]
28. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
Rathkey D; Khanal M; Murai J; Zhang J; Sengupta M; Jiang Q; Morrow B; Evans CN; Chari R; Fetsch P; Chung HJ; Xi L; Roth M; Filie A; Raffeld M; Thomas A; Pommier Y; Hassan R
J Thorac Oncol; 2020 May; 15(5):843-859. PubMed ID: 32004714
[TBL] [Abstract][Full Text] [Related]
30. PARP inhibition in UV-associated angiosarcoma preclinical models.
Weidema ME; Desar IME; Hillebrandt-Roeffen MHS; van Erp AEM; Masuzawa M; ; Flucke UE; van der Graaf WTA; Versleijen-Jonkers YMH
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2579-2590. PubMed ID: 34085099
[TBL] [Abstract][Full Text] [Related]
31.
Molenaar RJ; Radivoyevitch T; Nagata Y; Khurshed M; Przychodzen B; Makishima H; Xu M; Bleeker FE; Wilmink JW; Carraway HE; Mukherjee S; Sekeres MA; van Noorden CJF; Maciejewski JP
Clin Cancer Res; 2018 Apr; 24(7):1705-1715. PubMed ID: 29339439
[No Abstract] [Full Text] [Related]
32. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
33.
Wu S; Gao F; Zheng S; Zhang C; Martinez-Ledesma E; Ezhilarasan R; Ding J; Li X; Feng N; Multani A; Sulman EP; Verhaak RG; de Groot JF; Heffernan TP; Yung WKA; Koul D
Clin Cancer Res; 2020 Mar; 26(6):1395-1407. PubMed ID: 31852834
[TBL] [Abstract][Full Text] [Related]
34. PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Engert F; Schneider C; Weiβ LM; Probst M; Fulda S
Mol Cancer Ther; 2015 Dec; 14(12):2818-30. PubMed ID: 26438158
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
Chen C; Zhou H; Xu L; Xu D; Wang Y; Zhang Y; Liu X; Liu Z; Ma D; Ma Q; Chen Y
Apoptosis; 2010 Jul; 15(7):805-13. PubMed ID: 20349137
[TBL] [Abstract][Full Text] [Related]
36. The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model.
Hwang K; Lee JH; Kim SH; Go KO; Ji SY; Han JH; Kim CY
In Vivo; 2021; 35(4):2015-2023. PubMed ID: 34182476
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
[TBL] [Abstract][Full Text] [Related]
38. Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
Zhang R; Wang T; Lin J
Anticancer Res; 2021 May; 41(5):2277-2286. PubMed ID: 33952453
[TBL] [Abstract][Full Text] [Related]
39. Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations.
Mgoboza C; Okunlola FO; Akawa OB; Aljoundi A; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):495-504. PubMed ID: 35588345
[TBL] [Abstract][Full Text] [Related]
40. Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.
Snyder LA; Damle R; Patel S; Bohrer J; Fiorella A; Driscoll J; Hawkins R; Stratton CF; Manning CD; Tatikola K; Tryputsen V; Packman K; Mamidi RNVS
Mol Cancer Ther; 2022 Jul; 21(7):1115-1124. PubMed ID: 35499386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
